전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved56 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleBaylor College of MedicinePhase 1

CD30.CAR-EBVST cells (CD30.CAR-EBVST cells)

Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type; Classical Hodgkin Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 3Status Discontinued
CGTLimited DatastaleNational Heart, Lung, and Blood…Phase 2

ATLCAR.CD30 cells (ATLCAR.CD30 cells)

Lymphoma; Lymphoma, Non-Hodgkin · CD30

#CD30#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
AntibodyLimited DatastaleAmgenPhase 2

MT103 (Blinatumomab, Blinatumomab (MT103))

Non-Hodgkin's Lymphoma, Relapsed · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Phase2#monoclonal-antibody#Non-HodgkinsLymphoma+2
Trials 2Status Active
CGTLimited DatastaleYake Biotechnology Ltd.Phase 1

CD19-BAFF Targeted CAR T-cells (CD19-BAFF Targeted CAR T-cells)

Acute Lymphoblastic Leukemia,B-Cell; Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 2Status Recruiting
ADCLimited DatastaleSeagenPhase 2

brentuximab vedotin (Adcetris, Induction without Brentuximab Vedotin)

Hodgkin Lymphoma, Adult · Hodgkin Lymphoma, Adult

#HodgkinLymphomaAdult#ADC#Phase2#antibody-drug-conjugate#HodgkinLymphoma+2
Trials 2Status Recruiting
CGTLimited DatastaleNektar TherapeuticsPhase 1

Polymer-conjugated IL-15 Receptor Agonist NKTR-255 (Polymer-conjugated IL-15 Receptor Agonist NKTR-255)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 2Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Preclinical

ATLCAR.CD30 (ATLCAR.CD30)

Hodgkin Lymphoma, Adult · CD30

#CD30#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleGoethe UniversityPhase 2

MabCampath (Alemtuzumab, Alemtuzumab (MabCampath))

Adult Acute Lymphocytic Leukemia T-cell; Lymphoma, Lymphoblastic · Adult Acute Lymphocytic Leukemia T-cell

#AdultAcuteLymphocyticLeukemiaT-c#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19-chimeric-antigen-receptor-transduced T cells (Anti-CD19-chimeric-antigen-receptor-transduced T cells)

Leukemia, B-cell; Lymphoma, Hodgkins · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-Tumor Necrosis Factor (TNF, Anti-Tumor Necrosis Factor, Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) T cells)

Lymphoma, Large-Cell, Anaplastic; Enteropathy-Associated T-Cell Lymphoma · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A) [TECENTRIQ])

Lymphoma, Follicular · Lymphoma, Follicular

#LymphomaFollicular#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
CGTLimited DatastaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleBaylor College of MedicinePhase 1

C7R.CD30.CAR-EBVST cells (C7R.CD30.CAR-EBVST cells)

CD30-Positive Diffuse Large B-Cell Lymphoma; Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type · CD30

#CD30#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） (CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL); AML (Acute Myelogenous Leukemia) · Lymphoma, B-cell, Aggressive Non-Hodgkin

#LymphomaB-cellAggressiveNon-Hodg#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleGuangdong Zhaotai Cell Bio-tech…Phase 2

CAT19T2 (CD19 CAR T-Cell, CD19 CAR T-Cell(CAT19T2))

B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma, Unspecified · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

CD19 or CD20 CAR T cells briging HSCT (CD19 or CD20 CAR T cells briging HSCT)

Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 1

CD19 specific Chimeric Antigen Receptor T Cell (CD19 specific Chimeric Antigen Receptor T Cell)

Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CD19-PD1-CART Cell (CD19-PD1-CART Cell)

Lymphoma, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

CD19-TriCAR-T (CD19-TriCAR-T)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active

2 / 3 pages

← PreviousNext →